JW중외제약, 리바로젯 단일용량 1위의 의미…피타바 복합제 가능성 확인

Rivabrozet's achievement of market-leading status in dyslipidemia combination drugs demonstrates that clinical evidence and strategic market positioning can displace entrenched competitors, reshaping competition away from traditional ingredient-based hierarchies. JW Pharmaceutical's success illustrates how dual-channel sales strategy (hospitals and clinics) combined with pitavastatin differentiation creates competitive advantage in chronic disease management, signaling emerging market opportunities beyond established leaders. This milestone signals pharmaceutical industry evolution toward innovation-driven competition where safety profiles, clinical validation, and patient-tailored dosing increasingly determine market success.